破坏细胞循环机制:CREPT是癌症治疗的新兴目标
Umar Farooq1, Jun Li1, Zhijie Chang2
1Jinfeng Laboratory, No. 313 Jinyue Road, High-Tech Zone, Chongqing 401329, China.
Cancers
|July 29, 2025
概括
瘤中的细胞周期相关和表达升高蛋白 (CREPT) 通过激活关键途径驱动癌症. 向CREPT显示出逆转瘤生长和增强免疫疗法的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 瘤中的细胞循环相关和表达升高的蛋白质 (CREPT) 是一个转录辅助因子.
- 通过激活Wnt/β-catenin,STAT3和NF-κB/TNFR2.2等瘤原体信号通路,CREPT失调驱动瘤发生.
- 异常的CREPT表达与各种癌症患者的生存率差相关.
研究的目的:
- 审查CREPT在癌症中的多方面的作用.
- 探索CREPT在癌症的特征中的参与.
- 建议CREPT作为癌症治疗的治疗点.
主要方法:
- 审查涉及使用shRNA的CREPT淘汰的临床前研究.
- 对CREPT在新陈代谢调节,组织修复和微环境重塑方面的功能研究的分析.
- 检查针对CREPT的当前战略,包括基于miRNA的方法.
主要成果:
- 在临床前模型中,CREPT Knockdown 证明了持续的瘤生长回归.
- CREPT调节了多种促进癌症的信号通路.
- 新出现的证据突出显示了CREPT超出细胞周期控制的类功能.
结论:
- 向CREPT具有逆转瘤进展的重大潜力.
- 将CREPT抑制与免疫检查点抑制剂相结合可能会提高CREPT驱动癌症的疗效.
- 对直接CREPT抑制剂的进一步研究有必要进行临床应用.
相关概念视频
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Negative Regulator Molecules
36.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.0K


